📊 ENLV Key Takeaways
Is ENLV a Good Investment? Thesis Analysis
Enlivex Ltd. presents insufficient financial data for meaningful fundamental analysis, with no revenue, profitability metrics, or recent insider activity disclosed. The lack of available metrics severely limits the ability to assess financial health, operational efficiency, or growth quality, indicating either pre-revenue status or significant reporting gaps.
Why Buy ENLV? Key Strengths
- Operating in pharmaceutical sector with potential for high-value therapeutics
- Listed on Nasdaq suggesting some level of institutional oversight
- No disclosed long-term debt burden apparent
ENLV Investment Risks to Consider
- Complete absence of revenue and profitability data indicates pre-commercial or severely underperforming operations
- No visibility into cash position, liquidity, or burn rate creates inability to assess financial stability
- Zero insider purchases in last 90 days suggests lack of management confidence
- Only 1 metric available indicates incomplete or missing financial disclosures
- Pharmaceutical sector inherently high-risk with unproven product pipeline
Key Metrics to Watch
- Revenue generation and path to profitability
- Cash position and runway for operations
- Clinical trial progress and regulatory milestones
- Insider trading activity indicating management confidence
ENLV Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
ENLV Profitability Ratios
ENLV vs Healthcare Sector
How Enlivex Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ENLV Overvalued or Undervalued?
Based on fundamental analysis, Enlivex Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ENLV Balance Sheet & Liquidity
ENLV Growth Metrics (YoY)
ENLV SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Enlivex Ltd. (CIK: 0001596812)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Nov 14, 2024 | SC 13G | armistice-enlv093024.htm | View → |
| Jun 27, 2019 | SC 13G | sc13g0619hbl_enlivexthera.htm | View → |
| Jun 26, 2019 | SC 13G | sc13g0619kretzmer_enlivex.htm | View → |
| Jun 26, 2019 | SC 13G | sc13g0619kip_enlivexthera.htm | View → |
| Jun 19, 2019 | SC 13G | sc13g0619hobi_enlivextherap.htm | View → |
❓ Frequently Asked Questions about ENLV
What is the AI rating for ENLV?
Enlivex Ltd. (ENLV) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ENLV's key strengths?
Claude: Operating in pharmaceutical sector with potential for high-value therapeutics. Listed on Nasdaq suggesting some level of institutional oversight.
What are the risks of investing in ENLV?
Claude: Complete absence of revenue and profitability data indicates pre-commercial or severely underperforming operations. No visibility into cash position, liquidity, or burn rate creates inability to assess financial stability.
What is ENLV's revenue and growth?
Enlivex Ltd. reported revenue of N/A.
Does ENLV pay dividends?
Enlivex Ltd. does not currently pay dividends.
Where can I find ENLV SEC filings?
Official SEC filings for Enlivex Ltd. (CIK: 0001596812) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ENLV's EPS?
Enlivex Ltd. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ENLV a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Enlivex Ltd. has a SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ENLV stock overvalued or undervalued?
Valuation metrics for ENLV: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ENLV stock in 2026?
Our dual AI analysis gives Enlivex Ltd. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ENLV's free cash flow?
Enlivex Ltd.'s operating cash flow is N/A, with capital expenditures of N/A.
How does ENLV compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).